| DC7371 |
Balicatib
Featured
|
Balicatib(AAE-581) is a potent and selective inhibitor of cathepsin K; 10-100-fold more potent in cell-based enzyme occupancy assays than against cathepsin B, L, and S. |
|
| DCAPI1046 |
Balofloxacin |
Balofloxacin |
|
| DC11516 |
Balovaptan
Featured
|
Balovaptan (RG7314, RG-7314) is a potent, selective vasopressin-1 receptor antagonist.. |
|
| DC11057 |
Baloxavir acid
Featured
|
Baloxavir acid (S-033447) is an anti-influenza compound that potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses. |
|
| DC11056 |
Baloxavir marboxil
Featured
|
Baloxavir marboxil is a prodrug of S-033447. S-033447 is a small molecule inhibitor of the cap-dependent endonuclease of influenza A and B viruses. |
|
| DC9562 |
Balsalazide |
Balsalazide is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.
|
|
| DC9869 |
Bamaquimast |
Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138. |
|
| DC9117 |
Bambuterol HCl |
Bambuterol Hcl is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. |
|
| DC8298 |
BAN ORL 24
Featured
|
BAN ORL 24 is a potent, selective, competitive ORL1 non-peptide agonist. Displays 1000-fold selectivity over classical opioid receptors. |
|
| DC10502 |
BAPTA/AM(BAPTA-AM)
Featured
|
BAPTA/AM is a membrane permeable form of BAPTA, a selective chelator of Ca2+. |
|
| DC10385 |
BAR501
Featured
|
BAR501 is a potent and selective agonist of GPBAR1 with an EC50 of 1 μM. |
|
| DC10564 |
BAR 502
Featured
|
BAR502 is a dual FXR and GPBAR1 agonist with IC50 values of 2 μM and 0.4 μM, respectively. |
|
| DC20317 |
Barbadin |
Barbadin is a small molecule that selectively inhibits the β-arrestin/β2-adaptin interaction (IC50=19.1/15.6 uM for β-arrestin1/2) without effect on the formation of receptor/β-arrestin complexes. |
|
| DC4135 |
Bardoxolone methyl
Featured
|
Bardoxolone methyl (also known as “RTA 402” and “CDDO-methyl ester”) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. |
|
| DC5064 |
Baricitinib (INCB28050, LY3009104)
Featured
|
Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC8258 |
Baricitinib phosphate
Featured
|
Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC9935 |
Basmisanil(RG1662)
Featured
|
Basmisanil is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome. |
|
| DC10021 |
Batefenterol
Featured
|
Batefenterol（GSK961081，TD-5959）is a Muscarinic Antagonist and β2-Agonist possessing both muscarinic antagonist (MA) and β2-adrenoceptor agonist (BA) properties (MABA). |
|
| DC8133 |
Batimastat(BB-94)
Featured
|
Batimastat was used to study the role of MMP in proteolytic release of EGF in human follicular thyroid carcinoma cell line FTC-133. |
|
| DC12663 |
Bax channel blocker(BAI-1)
Featured
|
Bax channel blocker is a potent inhibitor of Bax-mediated mitochondrial cytochrome C release (IC50 = 0.52 μM). Suggested to inhibit Bax channel formation/activity. |
|
| DC23719 |
BAY 1024767 |
BAY 1024767 (BAY1024767) is a higly potent antagonist of androgen receptor (AR) wild-type (IC50=46 nM) and mutant forms located in the AR ligand-binding domain (LBD). |
|
| DC9939 |
BAY 1082439 |
BAY 1082439 is a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN. |
|
| DC20750 |
BAY 1143269 |
BAY 1143269 is a potent, selective, orally bioavailable inhibitor of MNK1 with enzyme IC50 of 40 nM at 2 mM ATP. |
|
| DC10376 |
BAY-1143572 |
BAY 1143572 is a highly selective, potent and orally available inhibitor of PTEFb/CDK9; inhibits the proliferation of AML cell lines with a median IC50 of 385 nM. |
|
| DC7869 |
BAY11-7082
Featured
|
BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM. Also inhibiting components of the ubiquitin system. |
|
| DC8038 |
Bay 11-7085
Featured
|
BAY 11-7085 is an irreversible inhibitor of TNFα-induced IκBα phosphorylation with an IC50 value of 10 μM. |
|
| DC23386 |
BAY 1238097 |
BAY 1238097 is a novel BET bromodomain inhibitor with IC50 of 50 nM, inhibits the interaction between BRD4, BRD3 or BRD2 and H4 with IC50 values of 63 nM, 609 nM and 2430 nM in the NanoBRET assay. |
|
| DC20589 |
BAY 1251152
Featured
|
BAY 1251152 (VIP152
) is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM, displays> 50-fold selectivity against other CDKs. |
|
| DC23745 |
BAY-2402234
Featured
|
BAY 2402234 (BAY2402234) is a novel potent, selective, orally bioavailable DHODH inhibitor with IC50 of 1.2 nM (human full-length DHODH). |
|
| DC7782 |
BAY 41-2272 |
Activator of soluble guanylyl cyclase (sGC); acts at a nitric oxide (NO)-independent regulatory site in the sGC α1 subunit. Inhibits platelet aggregation (IC50 = 36 nM) and phenylephrine-induced contractions of rabbit aorta (IC50 = 0.30 μM). Also reduces vascular smooth muscle growth through cAMP- and cGMP-dependent PKA and PKG pathways.. For the detailed information of BAY 41-2272, the solubility of BAY 41-2272 in water, the solubility of BAY 41-2272 in DMSO, the solubility of BAY 41-2272 in PBS buffer, the animal experiment (test) of BAY 41-2272, the cell expriment (test) of BAY 41-2272, the in vivo, in vitro and clinical trial test of BAY 41-2272, the EC50, IC50,and affinity,of BAY 41-2272, Please contact DC Chemicals. |
|
